Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, March 4, 2026. Sanofi announces today the filing of an amendment to its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF). This amendment notably includes additions to the report on corporate governance established in accordance with French law. ...
Communiqué de presse : Dépôt d’un amendement au Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel Dépôt d’un amendement au Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel Paris, le 4 mars 2026. Sanofi annonce avoir déposé ce jour un amendement à son Document d’Enregistrement Universel 2025 contenant le Rapport Financier Annuel auprès de l’Autorité des marchés financiers (AMF) en France. Cet amendement intègre notamment des compléments au (i) rapport de gestion et au (ii) rapport sur le gouvernement d’entreprise. Le document pe...
RUBIS: Transactions carried out within the framework of the share buyback programme (excluding transactions within the liquidity agreement) – 23 to 27 February 2026 Paris, 2 March 2026, 06:00pm Issuer Name: Rubis (LEI: 969500MGFIKUGLTC9742)Category of securities: Ordinary shares (ISIN: FR0013269123)Period: From 23 to 27 February 2026 Upon the authorisation granted by the Ordinary Shareholders’ Meeting held on 12 June 2025 to implement a share buyback programme, the Company carried out, between 23 and 27 February 2026, the repurchases of its own shares in view to transfer them to employee...
RUBIS: Opérations effectuées dans le cadre du programme de rachat d’actions (hors contrat de liquidité) du 23 au 27 février 2026 Paris, le 2 mars 2026, 18h00 Dénomination sociale de l’émetteur : Rubis (LEI : 969500MGFIKUGLTC9742)Catégorie de titres : Actions ordinaires (ISIN : FR0013269123)Période : Du 23 au 27 février 2026 Conformément à l’autorisation accordée par l’Assemblée Générale Ordinaire du 12 juin 2025 de mettre en place un programme de rachat d’actions, la Société a procédé, entre le 23 et le 27 février 2026, aux rachats d’actions afin de les céder à des salariés et/ou des mand...
Election of employee representatives to the Board of Directors of Novo Nordisk A/S Bagsværd, Denmark, 2 March 2026 – The employees in Novo Nordisk A/S have completed the election of employee representatives to the Board of Directors of Novo Nordisk A/S. The following employee representatives were elected for the next four years: Semsi Kilic Madsen (new)Mette Bøjer Jensen (re-elected)Elisabeth Dahl Christensen (re-elected)Désirée Jantzen Asgreen (new) The following were elected as substitutes for the employee-elected board members: Trine Hartvig KristiansenTamara SchmidtTanja VillumsenHa...
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 2 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initiated 4 February 2026, Novo Nordisk will repurch...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.